Conditions: Peanut Hypersensitivity
Keywords: TOPS Peanut allergy Peanut-induced allergy Allergy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: omalizumab
Intervention descriptions: intervention 1: SC repeating dose

Protocol document: